Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart, Inc. develops oral recombinant pill vaccines based on a proprietary delivery platform. The clinical-stage biotechnology company’s programs include vaccine candidates for coronavirus, norovirus and influenza, as well as a therapeutic human papillomavirus vaccine as its first immune-oncology indication. Its pill-based vaccines are designed for oral administration, storage and shipping without refrigeration, and avoidance of needle-stick risk.
Vaxart news centers on clinical data and scientific publications, business updates, financial results, financing arrangements, collaborations, intellectual property around adenovirus and TLR3 agonist oral vaccination technology, and governance changes as the company advances its oral vaccine pipeline.
Vaxart, Inc. plans to advance its oral COVID-19 vaccine candidate, VXA-CoV2-1, to Phase 2 testing in Q2 2021. The company reported a cash balance of $126.9 million as of December 31, 2020, reflecting significant capital influx from various funding sources. The fourth-quarter revenue was $356,000, down from $3.9 million in 2019, primarily due to a drop in royalty revenue. The net loss for Q4 2020 was $13.9 million, with R&D expenses increasing to $8.6 million driven by COVID-19 vaccine developments. A strategic conference call is scheduled for March 2, 2021.
Vaxart, a clinical-stage biotechnology company, will host a conference call and business update on March 2, 2021, at 4:30 PM ET. The company specializes in developing oral recombinant vaccines that are tablet-administered rather than injected. Vaxart aims to create vaccines for various diseases, including coronavirus, Norovirus, and seasonal influenza, using a proprietary delivery platform that eliminates the need for refrigeration. This innovative approach also reduces the risk of needle-stick injuries.
Vaxart, Inc. (NASDAQ: VXRT) announced preliminary results from its Phase 1 study of the oral COVID-19 vaccine candidate, VXA-CoV2-1. The study met its primary endpoint of safety and secondary endpoint of immunogenicity, showing potent CD8+ T-cell responses. The vaccine demonstrated potential protection against new COVID-19 variants by including both Spike and N proteins. Results from 495 subjects indicated no severe adverse events, and mild gastrointestinal reactions were the most common. Vaxart plans to advance the vaccine into Phase II studies.
Vaxart (NASDAQ: VXRT) announced findings from a study published in the American Journal of Preventative Medicine, revealing economic advantages of a potential norovirus vaccine. A computational model indicated that a vaccine priced up to $1,300 could yield cost savings for children under 5, while one costing up to $100 could be cost-effective for older adults. The study highlights norovirus's impact on public health, projecting significant reductions in symptomatic cases through vaccination. Vaxart plans to initiate three clinical trials in 2021.
Vaxart, a clinical-stage biotechnology company, announced new pre-clinical data showing its oral COVID-19 vaccine significantly reduced lung inflammation in hamster models. Published in Nature Medicine, the study highlighted a substantial reduction in viral load and robust antibody responses. CEO Andrei Floroiu emphasized the vaccine's room-temperature stability, enhancing transport and storage. Phase I trial data is anticipated next week. The selected vaccine candidate also targets the nucleocapsid protein, potentially improving cross-protection.
Vaxart, Inc. (NASDAQ: VXRT) will host an investor panel on November 19, 2020, featuring key opinion leaders discussing their oral vaccine technology aimed at combating COVID-19 and Norovirus. The panel includes insights on immunity, disease prevention, and Vaxart's investigational vaccines. Management will update on their Phase 1 trial for Norovirus and provide preclinical data for their oral COVID-19 vaccine candidate, VXA-CoV2-1. The company emphasizes the potential advantages of oral vaccines over traditional injections, including ease of distribution and administration.
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 – Vaxart, Inc. (NASDAQ: VXRT) announced participation in two upcoming virtual investor conferences. The Jefferies 2020 Virtual London Healthcare Conference will take place from November 17-19, with Vaxart's presentation scheduled for November 19 at 2:20 p.m. ET. Additionally, the Piper Sandler 32nd Annual Virtual Healthcare Conference is set for December 1-3. Vaxart focuses on developing oral vaccines for various infectious diseases, including COVID-19. For further details, visit their investors section.
Vaxart announced the completion of enrollment in its Phase 1 trial for VXA-CoV2-1, an oral COVID-19 vaccine candidate. The trial data show significant viral load reduction and strong antibody responses in a hamster model. The company reported a net loss of $8.1 million for Q3 2020, an increase from $5.3 million in Q3 2019, primarily due to higher operating expenses. Revenue dropped to $265,000, down from $454,000 in Q3 2019, attributed mainly to reduced contract activities with Janssen. Vaxart ended Q3 with $133.4 million in cash, boosted by a recent stock issuance.
Vaxart, Inc. (NASDAQ: VXRT) reported promising results from its Hamster Challenge Study for its oral COVID-19 vaccine candidate. The study indicated a significant reduction in lung viral load by 4-5 logs in vaccinated hamsters versus unvaccinated ones. Additionally, antibody response was strong, with serum IgG levels exceeding 10,000. The oral vaccine performed comparably to intranasal options in preventing weight loss and lung complications. CEO Andrei Floroiu emphasized the convenience of their room-temperature-stable oral vaccine, which could be a practical alternative to injectable vaccines.
Vaxart (NASDAQ: VXRT) released promising results from its Hamster Challenge Study, indicating that all hamsters receiving two oral doses of its COVID-19 vaccine candidate did not experience systemic weight loss, a key protective measure. Dr. Sean Tucker highlighted that these results validate the vaccine's potential against COVID-19 as the company prepares for human clinical trials. The study showed that unvaccinated hamsters lost significant weight and exhibited lung issues, whereas vaccinated ones maintained or gained weight (p0.001). Vaxart aims to provide a convenient oral vaccine solution.